MannKind Corporation (NASDAQ:MNKD) Files An 8-K Results of Operations and Financial Condition

116

MannKind Corporation (NASDAQ:MNKD) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On October10, 2017, we issued a press release announcing certain estimated financial results as of and for the three months ended September30, 2017, in addition to a registered direct offering of our common stock.The financial results included in the press release are preliminary and unaudited and may differ from what will be reflected in our condensed financial statements as of and for the three months ended September30, 2017. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1 Press Release dated October10, 2017

EXHIBIT INDEX

Exhibit Number

Description

99.1 Press Release dated October10, 2017


MANNKIND CORP Exhibit
EX-99.1 2 d469645dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   MannKind Announces $61 Million Registered Direct Offering of Common Stock WESTLAKE VILLAGE,…
To view the full exhibit click here

About MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

An ad to help with our costs